Amneal Pharmaceuticals, Inc. AMRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $1.75B+0.5% | $1.75B-0.2% | $1.75B+1.9% | $1.71B+0.4% | $1.71B+1.4% | |
| AvKARE | $738.33M-0.9% | $744.73M+5.7% | $704.37M+5.9% | $665.33M-1.1% | $672.7M+1.5% | |
| Other Operating Income by Business | ||||||
| Affordable Medicines | $7.06M+34.7% | $5.24M0.0% | $5.24M+2.3% | $5.12M0.0% | $5.12M— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Gross Profit by Business | ||||||
| Affordable Medicines | $702.64M+2.7% | $683.92M-3.8% | $711.23M+0.3% | $708.96M+2.1% | $694.6M+3.1% | |
| AvKARE | $157.26M+7.1% | $146.79M+15.1% | $127.57M+12.3% | $113.56M+7.2% | $105.96M+2.3% | |
| Specialty | $317.62M+12.4% | $282.59M+17.7% | $240.19M-4.7% | $252.06M+6.0% | $237.71M-2.1% | |
| Operating Income (Loss) by Business | ||||||
| Affordable Medicines | $390.95M+2.7% | $380.8M-2.5% | $390.7M-0.7% | $393.37M+0.3% | $392.3M+45.2% | |
| AvKARE | $93.1M+11.3% | $83.62M+27.6% | $65.54M+27.0% | $51.63M+16.1% | $44.46M+3.6% | |
| SG&A by Business | ||||||
| Affordable Medicines | $149.99M+5.3% | $142.38M+2.4% | $139.03M+4.7% | $132.81M+2.0% | $130.21M+0.5% | |
| AvKARE | $64.16M+1.6% | $63.18M+1.9% | $62.02M+0.1% | $61.93M+0.7% | $61.5M+1.3% | |
| Gain (Loss) from Litigation Settlement by Business | ||||||
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Other by Business | ||||||
| Affordable Medicines | $27.45M-3.4% | $28.41M-1.8% | $28.93M-0.4% | $29.05M-5.3% | $30.68M+1.4% | |
| Specialty | $5.24M-6.1% | $5.58M-8.3% | $6.09M+56.2% | $3.9M+25.4% | $3.11M+19.9% | |
| Restructuring and other charges by Business | ||||||
| Affordable Medicines | $2.97M0.0% | $2.97M+284% | $773K+10.4% | $700K+900% | $70K0.0% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Currency translation by Business | ||||||
| Affordable Medicines | -$3.7M-88.0% | -$1.97M+17.4% | -$2.38M-111% | -$1.13M— | —— | |
| AvKARE | $0— | $0— | $0— | $0— | —— | |
| Specialty | $0— | $0— | $0— | $0— | —— | |
| Product development and studies by Business | ||||||
| Affordable Medicines | $4.05M+17.4% | $3.45M+191% | -$3.8M-1,084% | -$321K-126% | $1.21M-67.9% | |
| Specialty | $8.97M+5.4% | $8.52M+0.9% | $8.44M+51.2% | $5.58M+69.5% | $3.29M+134% | |
| Regulatory fees by Business | ||||||
| Affordable Medicines | $8.79M+37.4% | $6.4M-23.4% | $8.35M+10.1% | $7.58M+38.2% | $5.49M0.0% | |
| Specialty | $0— | $0— | $0— | $0— | $0— | |
| Cost of goods sold by Business | ||||||
| Affordable Medicines | $1.05B-1.0% | $1.06B+2.4% | $1.04B+3.1% | $1.01B-0.8% | $1.01B+0.3% | |
| AvKARE | $581.07M-2.8% | $597.94M+3.7% | $576.81M+4.5% | $551.77M-2.6% | $566.74M+1.3% | |
| Materials and supplies by Business | ||||||
| Affordable Medicines | $31.86M+0.9% | $31.57M-18.2% | $38.59M-6.4% | $41.24M+5.3% | $39.15M-3.5% | |
| Specialty | $2.85M-4.8% | $3M+25.8% | $2.38M+105% | $1.16M+17.0% | $993K-18.7% | |
| R&D by Business | ||||||
| Affordable Medicines | $158.32M+1.5% | $156.01M-11.7% | $176.6M-1.1% | $178.58M+6.1% | $168.38M-2.0% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Affordable Medicines | $639.51M-0.6% | $643.21M-0.3% | $645.18M-0.4% | $647.56M-0.2% | $648.68M-0.2% | |
| AvKARE | $277.86M0.0% | $277.86M0.0% | $277.86M0.0% | $277.86M0.0% | $277.86M0.0% | |
| Specialty | $1.47B0.0% | $1.47B0.0% | $1.47B0.0% | $1.47B0.0% | $1.47B0.0% | |
| Employee compensation and benefits by Business | ||||||
| Affordable Medicines | $53.86M-1.0% | $54.37M+1.8% | $53.43M+5.4% | $50.71M+4.5% | $48.5M+4.2% | |
| Specialty | $44.77M+2.4% | $43.71M+5.4% | $41.49M+7.3% | $38.68M+4.7% | $36.94M+5.8% | |
| Facilities costs by Business | ||||||
| Affordable Medicines | $6.69M-2.1% | $6.83M-1.1% | $6.91M+2.3% | $6.76M+1.5% | $6.66M-0.9% | |
| Specialty | $1.24M-36.5% | $1.96M-42.6% | $3.41M-25.8% | $4.6M-14.2% | $5.36M-8.5% | |
| Milestones by Business | ||||||
| Specialty | $3M-50.0% | $6M+100% | $3M0.0% | $3M0.0% | $3M— | |
| Intellectual property legal development expenses by Business | ||||||
| Affordable Medicines | $7.17M-3.0% | $7.39M-7.4% | $7.98M+8.0% | $7.38M+14.7% | $6.44M+13.2% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $238K-2.1% | $243K— | —— | —— | —— | |
| Net revenue by Product | ||||||
| Auto-Injector | $226.55M-2.7% | $232.8M+0.5% | $231.6M+3.7% | $223.35M+3.9% | $215.04M+2.6% | |
| Biosimilar | $93.99M-6.2% | $100.23M-8.3% | $109.35M-11.1% | $123.02M-3.3% | $127.27M+1.5% | |
| Central nervous system | $349.19M+4.7% | $333.42M+9.2% | $305.26M+1.4% | $301.03M+6.9% | $281.51M+0.5% | |
| Distribution | $392.71M-3.9% | $408.46M+0.3% | $407.3M-1.3% | $412.69M-3.8% | $429.16M-1.1% | |
| Government label | $279.91M+3.6% | $270.11M+17.3% | $230.17M+24.9% | $184.35M+5.3% | $175.15M+9.5% | |
| Hormonal / allergy | $156.66M+1.1% | $154.93M+7.4% | $144.3M+3.9% | $138.89M+2.7% | $135.25M+3.7% | |
| Injectable | $176.39M+9.4% | $161.24M-6.1% | $171.76M+7.0% | $160.56M-2.7% | $165M-0.3% | |
| Institutional | $34.19M-3.4% | $35.38M-6.2% | $37.72M-8.6% | $41.27M-3.8% | $42.9M+0.4% | |
| International | $16.21M+33.7% | $12.13M+13.1% | $10.72M+19.9% | $8.94M+5.6% | $8.47M-5.4% | |
| Oral liquid | $61.37M-15.7% | $72.82M-11.9% | $82.7M-6.9% | $88.82M-6.5% | $95.04M-8.1% | |
| Oral solid | $718.53M-1.1% | $726.38M+0.8% | $720.63M+2.7% | $701.38M+0.3% | $699.08M+1.4% | |
| Other dosage forms | $242.61M-3.9% | $252.42M+3.8% | $243.24M+3.8% | $234.23M+8.8% | $215.34M+6.5% | |
| Other therapeutic classes | $47.13M+18.8% | $39.66M+22.6% | $32.36M+6.6% | $30.35M+1.1% | $30.01M+4.8% | |
| Subtotal dosage forms | $1.74B+0.3% | $1.73B-0.2% | $1.74B+1.9% | $1.71B+0.3% | $1.7B+1.4% | |
| Subtotal therapeutic classes | $552.98M+4.7% | $528.01M+9.6% | $481.92M+2.5% | $470.27M+5.3% | $446.76M+1.7% | |
| Transdermal | $218.41M+16.5% | $187.51M+5.2% | $178.18M+2.1% | $174.47M-4.9% | $183.46M+1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.